Events

Official Launch of Duplex Sequencing^TM Technology

Presentation by CEO Jesse Salk, MD, PhD
Ultra-Sensitive Residual Leukemia Detection with Patient-Specific Duplex Sequencing

View Talk

Poster Presented
Super CHIP: Duplex Sequencing Reveals Clonal Dynamics in Blood that are Magnitudes more Complex than Previously Recognized

View Poster

Presentation by CEO Jesse Salk, MD, PhD
Ultrasensitive Minimal Residual Disease Detection By Duplex Sequencing

Abstract
Duplex Sequencing enables an unprecedented level of NGS accuracy, with error rates below one-in-ten-million. The technology is ideally suited to detection of residual cancer (MRD), where lingering tumor cells are vastly outnumbered by normal cells. Here we present Duplex Sequencing-based MRD data from three clinical studies in acute myeloid leukemia.

Presentation by Jake Higgins
Clonal Landscapes of Hematologic Malignancies Redefined by Ultra-Sensitive Duplex Sequencing

View Poster Presented at Event

View Posters Presented and Abstract Information

Presentation by Jake Higgins
“Duplex Sequencing for Ultra-Low Frequency Mutation Detection in Hematological Malignancies”

View Poster Presented at Event

Presentation by CEO Jesse Salk, MD, PhD
Genetic susceptibility and biologic markers of carcinogen exposure

View Posters Presented at Event

View Poster Presented at Event